‘Impressive Results’ With CAR T-cell in R/R Follicular Lymphoma
Patients with relapsed or refractory (r/r) follicular lymphoma live longer when they are treated with the novel anti-CD19 chimeric antigen
Read morePatients with relapsed or refractory (r/r) follicular lymphoma live longer when they are treated with the novel anti-CD19 chimeric antigen
Read more